Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05090189
Other study ID # The ENRG Study
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 27, 2021
Est. completion date November 2023

Study information

Verified date October 2021
Source University of Sao Paulo
Contact Bruno Gualano, PhD
Phone 551126618022
Email gualano@usp.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This parallel-group randomized, controlled, clinical trial aims to investigate the influence of a 6-month home-based, remotely-monitored, exercise training intervention on musculoskeletal health in patients with Systemic Lupus Erythematosus who have undergone glucocorticoid pulse therapy.


Description:

Glucocorticoid treatment is a frequently prescribed to individuals with autoimmune diseases, such as Systemic Lupus Erythematosus, due to its anti-inflammatory effects. This treatment strategy has proven clinical benefits, but it can also adversely influence musculoskeletal health. Glucocorticoid pulse therapy is a particularly intensive treatment strategy, commonly used when the disease state is at its most active. Patients who undergo pulse therapy have a high risk of muscle and bone loss, and exercise training is a promising adjunct therapy to potentially ameliorate these adverse effects, but the feasibility and efficacy of this approach has yet to be investigated. The aim of this study, therefore, is to conduct a parallel-group, controlled, randomized clinical trial, to investigate the feasibility and efficacy of a home-based, remotely-monitored, exercise training intervention on musculoskeletal health in patients with Systemic Lupus Erythematosus who have undergone glucocorticoid pulse therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date November 2023
Est. primary completion date August 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Premenopausal women aged 18 to 45 diagnosed with Systemic Lupus Erythematosus according to SLICC criteria; - Medical indication and prescription for glucocorticoid pulse therapy; - Access to Internet and any device that allows for participation in exercise training online lessons (such as smart phone, laptop or personal computer); - Willingness to participate in an exercise training program. Exclusion Criteria: - Any physical, mental, neurological or musculoskeletal health impairment that contra-indicates exercise training. - Use of medical therapy that alters bone metabolism, such as bisphosphonates, teriparatide and denosumab; - Receiving prescription for multiple glucocorticoid pulse therapies mid-intervention; - Being currently enrolled or having enrolled in a structured exercise training program in the last 6 months (defined as at least 2 planned, structures sessions of exercise training per week); - Having a vertebral fracture at the moment of enrollment (identified by Vertical Fracture Assessment), or high risk for fracture (defined as low hip or spine bone mass [z-score < -3] or history of fragility fractures).

Study Design


Intervention

Other:
Exercise Training
The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week "blocks", which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period.

Locations

Country Name City State
Brazil Clinical Hospital of the School of Medicine, University of Sao Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
Bruno Gualano

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bone health Assessed by dual-energy X-ray absorptiometry, high resolution peripheral quantitative computed tomography and blood bone biomarkers (C-terminal telopeptide [ß-CTX-1], procollagen type 1 amino-terminal propeptide [P1NP], sclerostin, osteocalcin). Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Muscle health Assessed by dual-energy X-ray absorptiometry (fat-free mass), one-repetition maximum test (bench press and leg extension), and muscle functionality tests (timed-up-and-go, timed-stands, handgrip). Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Aerobic capacity Assessed by maximal graded ergospirometric test. Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Body composition Assessed by dual-energy X-ray absorptiometry (fat mass, percentage body fat, lean mass), body mass index, waist and hip circumferences. Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Intervention feasibility and acceptability Assessed by feasibility metrics: Recruitment Capacity, Acceptability and Suitability, Resources, and Intervention Efficacy. Entire study duration.
Secondary Cardiovascular risk Assessed by Framingham Risk Score Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Proinflammatory cytokines Assessed by interferon gamma (IFN-?), interleukin 10 and 6 (IL-10, IL-6), tumor necrosis factor alpha (TNF-a), and soluble TNF receptors (sTNFR1 e sTNFR2) assays. Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Nutritional intake Assessed by three non-consecutive food recalls. Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Disease activity Assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary General quality of life 36-Item Short Form Survey (SF-36). Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Disease-related quality of life Assessed by Systemic Lupus Erythematosus Quality of Life Questionnaire (SLEQOL) Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Physical activity levels Assessed by International Physical Activity Questionnaire (IPAQ) Baseline (PRE), after 3 months (MID), and after 6 months (POST).
Secondary Current and past bone-loading physical activity levels Assessed by Bone-Specific Physical Activity Questionnaire (BPAQ). Baseline (PRE).
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2